

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/539,262
Filing Date	November 13, 2006
First Named Inventor	RAMAKRISHNA, Venkata Satya..
Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	SUB 0007 US

Sheet	1	of	3
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						T <sup>6</sup>
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO2000072815-A	12-07-2000	Neurim Pharmaceuticals		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/539,262
		Filing Date	November 13, 2006
		First Named Inventor	RAMAKRISHNA, Venkata Satya...
		Art Unit	1626
		Examiner Name	SHAMEEM, Golam M.
Sheet 2	of 3	Attorney Docket Number SUB 0007 US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		CASTNER, Stacy A. et al, "Animal Models of Working Memory: Insights for Targeting...", Psychopharmacology, 2004, pp. 111-125, Vol. 174, Springer-Verlag, USA	
		LINDNER, Mark D. et al, "An Assessment of the Effects of Serotonin 6...", JPET, 2003, pp. 682-691, Vol. 307, Am. Society for Pharmacology and Experimental Therapeutics, USA	
		BENTLEY, Jane C. et al, "Investigation of Stretching Behaviour Induced by...", British Journ of Pharm, 1999, pp. 1537-1542, Vol. 126, Stockton Press, UK	
		HIRST, Warren D. et al, "SB-39985 is a Potent, Selective 5 - HT6 Receptor...", European Journal of Pharmacology, 2006, UK	
		"Target Indication: Obesity; Cognitive Impairment Associated with Alzheimer's Disease and Schizophrenia", World Health Organization 2006 Statistics, 2006 EPIX Pharmaceuticals	
		CHUANG, Aaron T. T. et al, "5-HT6 Receptor Antagonist SB-742457..." UK	
		SCHREIBER, RUDY et al, "Effects of the Novel 5-HT6 Receptor Antagonist RO4368554...", European Neuropsychopharmacology, 2006, pp. 1-12, Elsevier, USA	
		SIKAZWE, Donald et al, "Binding of Sulfonyl-Containing Arylalkylamines...", J. Med. Chem., 2006, pp. 5217-5225, Vol. 49, American Chemical Society, USA	
		FISAS, Angels et al., "Chronic 5-HT6 Receptor Modulation by E-6837...", British Journ of Pharmacology, 2006, pp. 1-11, Nature Publishing Group, UK	
		HOLENZ, Jorg et al, "Medicinal Chemistry Strategies to 5-HT6 Receptor...", Drug Discovery Today, 2006, pp. 283-299, Vol. 11, Elsevier Ltd	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

HEAL, D.J. et al, "Selective 5-HT<sub>6</sub> Receptor Ligands: Progress in the Development...", Pharmacology & Therapeutics, 2007, pp. 207-231, Vol. 117, Elsevier Inc.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*